Trial results show drug prevents diabetes
Rosiglitazone (Avandia, GlaxoSmithKline) reduced the risk of developing Type 2 diabetes by 62%, according to study results presented at the 42nd Annual Meeting of the European Association for the Study of Diabetes.
Rosiglitazone (Avandia, GlaxoSmithKline) reduced the risk of developing Type 2 diabetes by 62%, according to study results presented at the 42nd Annual Meeting of the European Association for the Study of Diabetes. The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial evaluated 5,269 patients worldwide to determine whether the ACE inhibitor ramipril and/or rosiglitazone prevented the disease from developing. Study patients had an average age of 55 years with glucose levels that were starting to rise but did not yet have diabetes. Patients received 8 mg per day of rosiglitazone, 15 mg per day of ramipril, or placebo for three years. Results showed that ramipril did not reduce the risk of diabetes. To see more Hot off the Press news articles, click here.To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
